A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Pegylated Interferon-a 2B in Imatinib-naïve Gastrointestinal Stromal Tumour (GIST) Patients.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Imatinib (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Biomarker; Therapeutic Use
- 24 Aug 2010 Merck and Co added as trial sponsor and Schering/Merck as lead trial centre as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Sep 2008 Status changed from recruiting to active, no longer recruiting.